Solid Tumors

- **VAR0141**
  - Phase I/Ib
  - CPI-444
  - Single Agent & Combo w/ Atezolizumab
  - In Selected Incurable Cancers
  - PI: Kummar
  - Corvus Pharmaceuticals

- **VAR0143**
  - Phase 1/2
  - Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb)
  - JTX-2011
  - Alone or in Combination With Nivolumab in Adult Subjects
  - with Advanced Refractory Solid Tumor Malignancies
  - PI: Kummar
  - Bayer HealthCare AG

- **VAR0146**
  - Phase I Anti-C4.4a Antibody Drug Conjugate BAY 1129980 in Advanced Solid Tumors Known to Express C4.4a
  - PI: Kummar
  - Plexxicon

- **VAR0129**
  - Phase I/IIa
  - PLX8394 in Patients with Advanced, Unresectable Solid Tumors
  - PI: Kummar
  - Pfizer

- **Part 2: BRAF Activating Mutation**

- **VAR0129**
  - Phase I/IIa
  - PF-06647020 in Adult Advanced Solid Tumors
  - PI: Kummar
  - Pfizer

- **Part 2: Triple negative breast cancer or target expressing non small cell lung cancer**

- **VAR0130**
  - Phase I
  - PF-06647020 in Adult Advanced Solid Tumors
  - PI: Kummar
  - Pfizer

- **VAR0113**
  - Phase I
  - Dose Escalation Trial of HuSF9-G4 in Advanced Solid Malignancies
  - PI: Sikic
  - Stanford

- **VAR0148**
  - Phase I
  - MGD009 in Unresectable/Metastatic B7-H3-Expressing Neoplasms
  - PI: Kummar
  - MacroGenics

- **VAR0152**
  - Phase 1/2
  - TRK Inhibitor LOXO-195 in NTRK Fusion-Positive Cancers
  - PI: Kummar
  - Loxo Oncology

- **VAR0154**
  - Phase II
  - TRK Inhibitor LOXO-195 in NTRK Fusion (Previously Treated) / Non-Fusion NTRK Altered Cancers
  - PI: Kummar
  - Loxo Oncology

- **VAR0136**
  - Phase II
  - Basket Study of the Oral TRK Inhibitor LOXO-101 in NTRK Fusion-Positive Tumors
  - PI: Kummar
  - Loxo Oncology

---

**KEY**

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

---

Please mark up a copy using black ink and fax changes to 725-9204